Tesaro gets its PD-1 reg­is­tra­tion study start­ed, hunt­ing ac­cel­er­at­ed OK; Ul­tragenyx hus­tles in­to PhI­II

Tesaro $TSRO has launched a reg­is­tra­tion study for its PD-1 drug TSR-042, which was de­vel­oped in a col­lab­o­ra­tion with Anap­tys­Bio. The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.